AtheroNova Investor Presentation

AtheroNova Inc. is an early stage biotech company focused on discovery, research, development and licensing of novel compounds to reduce or regress atherosclerotic plaque deposits. Atherosclerotic plaque, which progressively narrows and blocks arteries, is the main underlying pathology of cardiovascular disease and the leading killer in industrialized nations worldwide. The Company's focus on compounds to reduce or eliminate atherosclerotic plaque deposits addresses the most lucrative segments of the multi-billion dollar prescription drug market: cardiovascular disease and stroke prevention.

Key Investment Considerations

•$41+ Billion market potential
•Strong IP protection
•Identifiable milestones
•Potentially lower risk of safety or efficacy problems than is typical in drug development
•Strong management team with successful track record
•Capital structure

Category:

Science & Technology

Tags:

• atherosclerosis
• stroke
• heart disease
• statins
• lipid
• peripheral artery disease
• ed